"Chinese peptides" is searched as if it names a different product. Mostly it names a different route to the same one. Most bulk peptide powder listed with FDA for the US market is made by companies in China, including material that reaches buyers through US compounders and research vendors. What changes between a factory-direct order and a vendor's vial is not usually the molecule's origin but who, if anyone, has tested the lot — and whether a buyer can check. This page sets out what FDA's own files show, with dates, and what they do not. It does not rank or recommend any supplier; how brands appear on this site is on our disclosure page.
Where FDA's directory says the powder is made
FDA's National Drug Code directory lists every product a firm registers for the US market, including "bulk ingredient" — the raw powder compounders and manufacturers buy. We queried it through openFDA on 2026-09-25 for four GLP-1 peptides and sorted each listing by the labeler's name:
| Peptide | Bulk-ingredient listings | Labelers named as mainland-Chinese companies | Share |
|---|---|---|---|
| Semaglutide | 90 | 70 | 78% |
| Tirzepatide | 72 | 59 | 82% |
| Liraglutide | 40 | 27 | 68% |
| Retatrutide | 12 | 12 | 100% |
| All four | 214 | 168 | 79% |
The rest are Indian manufacturers, a handful of European firms (Novo Nordisk's own entries among them), one Taiwanese firm, and US-based firms (Lilly and several distributors), whose listings do not show where their powder was made; so if anything, the Chinese share of the physical material is understated. The classification is ours, by labeler name; the directory itself carries no country field, and a reader can repeat it with the same query.
Retatrutide is the clearest case. It has no marketing approval in any country and is still in Lilly's trials, yet all twelve bulk listings are Chinese, in packages from a 1 g bottle to a 7 kg drum. Our retatrutide reconstitution page lists the labelers; our peptide sources explainer shows the same pattern in FDA's other file, the drug master files, where every active retatrutide holder is in China or India.
One limit binds everything above: a listing is a registration the firm makes, not an FDA approval, and it says nothing about whether any shipment was tested.
What FDA found when it looked at GLP-1 ingredient makers
For GLP-1 ingredients only, FDA has published what its evaluations found. On 2025-09-05 it announced a "green list": GLP-1 active ingredients may enter the US without detention only from firms FDA has inspected or evaluated and found compliant; "APIs from other sources are subject to detention without physical examination." The mechanism is Import Alert 66-80, whose page was last published on 2026-09-21. Its reasons for the alert, as read on 2026-09-25:
- Of 48 GLP-1 ingredient sites FDA evaluated, 21% were noncompliant.
- FDA encountered "a pattern of sites that register as GLP-1 API manufacturers, offer GLP-1 APIs for import, refuse to answer FDA's requests".
Chinese manufacturers appear on the green list as well as off it. That is the point a buyer can use: origin does not decide compliance; an inspection result does, and FDA publishes which firms passed for this one class of molecule.
One inspection, in detail
FDA's warning letter to Harbin Jixianglong Biotech, dated 2026-05-01, shows what a noncompliant finding looks like. The firm makes peptide ingredients including GLP-1s; FDA inspected it in November 2025. The letter states it shipped to the US without completing validation of its assay and related-substances methods — the tests for strength and impurities — and without completing verification of its bacterial endotoxin test, and that it lacked appropriate microbiological release specifications. The firm agreed to recall the two semaglutide batches it had distributed in the United States; FDA placed it on Import Alert 66-40 and removed it from the green list. It is also one of the seven retatrutide bulk labelers in the table above. The letter sits on our FDA warning-letter tracker with the other letters to sellers and makers.
A finished certificate of analysis from such a plant would still show a purity figure. That is why a certificate's number is only as good as the method behind it, which is the subject of our guide to reading a certificate of analysis.
Outside the GLP-1 class, there is no list
The green list covers GLP-1 ingredients because those have approved drugs and a compounding market FDA polices. BPC-157, TB-500 and the other research-market peptides have no approved use in the US, no green list and no published inspection outcomes. FDA's July 2026 compounding reviews found BPC-157 not well characterised as a substance, citing missing data on impurities, aggregates and endotoxin — set out on our BPC-157 side effects page. For these compounds, factory-direct and vendor-bought material alike rest on whatever testing the seller publishes; the "research use only" label on the vial changes nothing about that, as our research-use-only explainer shows.
What enforcement has looked like
The Justice Department announced on 2026-04-01 the indictment of a Utah osteopathic physician alleged to have obtained unapproved peptides from China through a middleman between February 2024 and April 2025 — including tirzepatide, semaglutide and retatrutide — and to have supplied them to patients under labels that did not name the manufacturer. An indictment is an allegation, and the defendant is presumed innocent unless proven guilty. The case is recorded here for what it shows about the channel, not about any person. FDA's own letters to research-peptide sellers, by date, are on our warning-letter tracker.
What this does and does not tell a buyer
It tells you that "made in China" is the normal condition of bulk peptide powder, not a special category, and that the meaningful questions are elsewhere: was this lot tested for identity, strength, impurities and endotoxin; by whom; is the report tied to the lot; and can it be checked. Who publishes that for the research market, and how, is on our page on who tests peptide vendors; what each test covers is on our peptide testing page.
It does not tell you anything about a specific factory or seller beyond what FDA has published, and this site has not yet completed its own test orders under its published methodology. Nothing here is a recommendation to buy from, or avoid, any supplier.
Sources and dates
Read 2026-09-25: openFDA NDC directory, product_type:"BULK INGREDIENT" for semaglutide, tirzepatide, liraglutide and retatrutide (214 listings; labeler names classified by us); FDA Import Alert 66-80 (published 2026-09-21), reasons for alert; FDA press announcement of 2025-09-05 launching the GLP-1 green list; FDA warning letter to Harbin Jixianglong Biotech Co., Ltd. (reference 723330, 2026-05-01); US Attorney's Office, District of Utah, press release of 2026-04-01; FDA's 2026-05-11 BPC-157 evaluation for the July 2026 compounding advisory committee. Corrections go to the contact page.